Nefrocarnit® (Levocarnitine)

Levocarnitine, the active ingredient in Nefrocarnit®, is a carnitine supplement presented as an oral tablet for oral use. It is indicated for primary and secondary carnitine deficiency and helps support fatty‑acid metabolism in various metabolic disorders.

GNH USA supplies Nefrocarnit® as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is marketed in the European Union as an over‑the‑counter nutritional supplement. All shipments comply with EU GMP standards and are traceable through batch certification. This ensures consistent product quality for patients and healthcare providers.

Nefrocarnit® (levocarnitine) is used to address disorders of carnitine metabolism and related fatty‑acid oxidation pathways.

- Primary carnitine deficiency: restores intracellular carnitine levels to improve energy production. - Secondary carnitine deficiency: replenishes carnitine lost due to renal loss, dialysis or certain medications, aiding metabolic stability. - Metabolic disorders affecting fatty‑acid oxidation: supports β‑oxidation, helping reduce accumulation of fatty acids and associated symptoms.

Oral levocarnitine is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes, usually transient. - Abdominal cramps: discomfort in the lower abdomen. - Diarrhea: loose stools that resolve with continued use. - Fish‑like body odor: due to metabolite excretion. - Headache: mild tension‑type headaches.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Stevens‑Johnson syndrome: rare skin eruption with mucosal involvement. - Hyperkalemia: elevated serum potassium levels, especially in renal impairment. - Severe rash: extensive erythema or urticaria. - Hepatotoxicity: abnormal liver enzymes in susceptible individuals.

Before initiating levocarnitine therapy, consider the following precautions.

- Renal impairment: monitor serum carnitine levels and adjust dose if needed. - Thyroid disorders: assess thyroid function before initiating therapy. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Concomitant valproate therapy: watch for increased risk of hepatotoxicity. - Drug interactions: review patient medication list for potential interactions. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Levocarnitine may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Valproic acid: may increase risk of hepatotoxicity. - Cisplatin: may exacerbate nephrotoxicity.

Moderate Interactions (Monitor Closely): - Carbapenem antibiotics: may reduce carnitine absorption. - Hemodialysis: may remove levocarnitine, requiring supplemental dosing. - Thyroid hormone therapy: may alter carnitine metabolism.